Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C27H34O11 |
Molecular Weight | 534.5523 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 9 / 9 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]12CO[C@H](C3=CC=C(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C(OC)=C3)[C@@]1([H])CO[C@H]2C5=CC=C(OC)C(OC)=C5
InChI
InChIKey=KFFCKOBAHMGTMW-LGQRSHAYSA-N
InChI=1S/C27H34O11/c1-32-17-6-4-13(8-19(17)33-2)25-15-11-36-26(16(15)12-35-25)14-5-7-18(20(9-14)34-3)37-27-24(31)23(30)22(29)21(10-28)38-27/h4-9,15-16,21-31H,10-12H2,1-3H3/t15-,16-,21+,22+,23-,24+,25-,26+,27+/m0/s1
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/23122079 | https://www.ncbi.nlm.nih.gov/pubmed/23751215Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/27323762 https://www.ncbi.nlm.nih.gov/pubmed/24995500
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23122079 | https://www.ncbi.nlm.nih.gov/pubmed/23751215
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/27323762 https://www.ncbi.nlm.nih.gov/pubmed/24995500
Phillyrin, an active ingredient found in many medicinal plants and certain functional foods, elicits anti-obesity and anti-inflammatory properties in vivo. Phillyrin is one of the main chemical constituents of Forsythia suspensa (Thunb.), which has shown to be an important traditional Chinese medicine. Phillyrin, has being shown to possess various bioactivities, including anti-inflammatory, anti-oxidant, and antiviral activities. It has being reported that Phillyrin attenuates high glucose-induced lipid accumulation in human HepG2 hepatocytes through the activation of LKB1/AMP-activated protein kinase-dependent signalling.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL613740 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27323762 |
|||
Target ID: GO:0006954 |
18.9 µM [IC50] | ||
Target ID: CHEMBL2096907 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23122079 |
|||
Target ID: CHEMBL2094253 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11345691 |
45.6 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27323762
i.p., 10 or 20 mg/kg/day for 3 days
Route of Administration:
Intraperitoneal
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11345691
Phillyrin inhibits release of the cyclo-oxygenase metabolites prostaglandin E2 (IC50 value 45.6 uM) and to a lesser extent reducing thromboxane B2 levels (IC50 value 168 uM) in human platelets
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
m8704
Created by
admin on Sat Dec 16 08:49:15 GMT 2023 , Edited by admin on Sat Dec 16 08:49:15 GMT 2023
|
PRIMARY | Merck Index | ||
|
Phillyrin
Created by
admin on Sat Dec 16 08:49:15 GMT 2023 , Edited by admin on Sat Dec 16 08:49:15 GMT 2023
|
PRIMARY | |||
|
487-41-2
Created by
admin on Sat Dec 16 08:49:15 GMT 2023 , Edited by admin on Sat Dec 16 08:49:15 GMT 2023
|
PRIMARY | |||
|
DTXSID40197589
Created by
admin on Sat Dec 16 08:49:15 GMT 2023 , Edited by admin on Sat Dec 16 08:49:15 GMT 2023
|
PRIMARY | |||
|
VE9P4964MG
Created by
admin on Sat Dec 16 08:49:15 GMT 2023 , Edited by admin on Sat Dec 16 08:49:15 GMT 2023
|
PRIMARY | |||
|
300000044122
Created by
admin on Sat Dec 16 08:49:15 GMT 2023 , Edited by admin on Sat Dec 16 08:49:15 GMT 2023
|
PRIMARY | |||
|
101712
Created by
admin on Sat Dec 16 08:49:15 GMT 2023 , Edited by admin on Sat Dec 16 08:49:15 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD